Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers

Краткое содержание

The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Kite Pharma, Inc. ("Kite") located in Santa Monica, CA to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.